CN104334193A - 生长激素释放肽受体反向激动剂或拮抗剂用于治疗睡眠障碍的用途 - Google Patents

生长激素释放肽受体反向激动剂或拮抗剂用于治疗睡眠障碍的用途 Download PDF

Info

Publication number
CN104334193A
CN104334193A CN201380029429.7A CN201380029429A CN104334193A CN 104334193 A CN104334193 A CN 104334193A CN 201380029429 A CN201380029429 A CN 201380029429A CN 104334193 A CN104334193 A CN 104334193A
Authority
CN
China
Prior art keywords
base
patient
treatment
administration
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380029429.7A
Other languages
English (en)
Chinese (zh)
Inventor
W·S·丹尼
M·杰克逊
G·索南伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Pfizer Inc
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN104334193A publication Critical patent/CN104334193A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380029429.7A 2012-06-04 2013-05-21 生长激素释放肽受体反向激动剂或拮抗剂用于治疗睡眠障碍的用途 Pending CN104334193A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261655177P 2012-06-04 2012-06-04
US61/655,177 2012-06-04
US201361812416P 2013-04-16 2013-04-16
US61/812,416 2013-04-16
PCT/IB2013/054177 WO2013182933A1 (en) 2012-06-04 2013-05-21 Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders

Publications (1)

Publication Number Publication Date
CN104334193A true CN104334193A (zh) 2015-02-04

Family

ID=48700662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380029429.7A Pending CN104334193A (zh) 2012-06-04 2013-05-21 生长激素释放肽受体反向激动剂或拮抗剂用于治疗睡眠障碍的用途

Country Status (16)

Country Link
US (1) US9370516B2 (ru)
EP (1) EP2854856B1 (ru)
JP (1) JP6165852B2 (ru)
KR (1) KR101708989B1 (ru)
CN (1) CN104334193A (ru)
AU (1) AU2013273263B2 (ru)
BR (1) BR112014029577A2 (ru)
CA (1) CA2874196C (ru)
ES (1) ES2716303T3 (ru)
HK (1) HK1202459A1 (ru)
IL (1) IL235883A0 (ru)
MX (1) MX2014014813A (ru)
RU (1) RU2600895C2 (ru)
SG (1) SG11201407387UA (ru)
WO (1) WO2013182933A1 (ru)
ZA (1) ZA201408672B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105175272A (zh) * 2015-08-31 2015-12-23 吴玲 制备r-5-溴-1-氨基茚满的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008286A2 (en) * 2006-07-12 2008-01-17 Merck & Co., Inc. Substituted pyrazoles as ghrelin receptor antagonists
US20110230461A1 (en) * 2010-03-19 2011-09-22 Bhattacharya Samit K 2,3-dihydro-1h-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
MXPA05006781A (es) * 2002-12-20 2005-09-30 Mclean Hospital Corp Compuestos para la normalizacion del ciclo de dormir / despertar.
US20050171132A1 (en) * 2003-09-26 2005-08-04 Zhili Xin Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists
US20090149512A1 (en) * 2004-05-14 2009-06-11 Novo Nordisk A/S Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases
US8309530B2 (en) * 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008286A2 (en) * 2006-07-12 2008-01-17 Merck & Co., Inc. Substituted pyrazoles as ghrelin receptor antagonists
US20110230461A1 (en) * 2010-03-19 2011-09-22 Bhattacharya Samit K 2,3-dihydro-1h-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALFONSO ABIZAID ET.AL: "Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite", 《THE JOURNAL OF CLINICAL INVESTIGATION》 *
VIRGINIE TOLLE ET.AL: "Ultradian Rhythmicity of Ghrelin Secretion in Relation with GH, Feeding Behavior, and Sleep-Wake Patterns in Rats", 《ENDOCRINOLOGY》 *
德温特数据库: "Suppressing food intake or appetite used for reducing body weight or treating obesity, involves administering ghrelin or preproghrelin small-interfering RNA, or ghrelin peptide antagonist to mammalian subject", 《德温特数据库》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105175272A (zh) * 2015-08-31 2015-12-23 吴玲 制备r-5-溴-1-氨基茚满的方法

Also Published As

Publication number Publication date
JP6165852B2 (ja) 2017-07-19
KR20150013236A (ko) 2015-02-04
CA2874196A1 (en) 2013-12-12
US9370516B2 (en) 2016-06-21
JP2015518876A (ja) 2015-07-06
MX2014014813A (es) 2015-02-12
WO2013182933A1 (en) 2013-12-12
AU2013273263A1 (en) 2014-11-27
RU2600895C2 (ru) 2016-10-27
EP2854856B1 (en) 2019-01-23
EP2854856A1 (en) 2015-04-08
ES2716303T3 (es) 2019-06-11
US20150119381A1 (en) 2015-04-30
CA2874196C (en) 2016-12-06
AU2013273263B2 (en) 2017-08-24
KR101708989B1 (ko) 2017-02-21
SG11201407387UA (en) 2014-12-30
RU2014146109A (ru) 2016-07-27
HK1202459A1 (en) 2015-10-02
BR112014029577A2 (pt) 2017-06-27
ZA201408672B (en) 2016-09-28
IL235883A0 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
CN101880276B (zh) 作为食欲素受体拮抗剂的取代的二氮杂环庚烷化合物
CN103874695B (zh) 2‑吡啶基氧基‑4‑腈食欲素受体拮抗剂
CN103476258B (zh) 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
JP5076159B2 (ja) アセチルコエンザイムａカルボキシラーゼ（ａｃｃ）阻害薬としてのスピロクロマノン誘導体
CN103958524B (zh) 稠合的二环噁唑烷酮cetp抑制剂
JP5319550B2 (ja) 置換スピロクロマノン誘導体
CN101627028B (zh) 作为食欲素受体拮抗剂的取代的二氮杂环庚烷化合物
US8524730B2 (en) Spirochromanone carboxylic acids
JP2010515734A (ja) スピロクロマノン誘導体
CN102272103A (zh) 异烟酰胺食欲素受体拮抗剂
EP1841419A1 (en) Cathepsin k inhibitors and obesity
CN102271511A (zh) 可用作抗糖尿病剂的新颖的环状苯并咪唑衍生物
EP2528603A1 (en) Pharmaceutical compositions for the treatment of pain and other indicatons
CN101466698A (zh) 作为缩胆囊素-1受体调节剂的取代的咪唑4-甲酰胺类化合物
JP5319518B2 (ja) インドールジオン誘導体
CN101605788A (zh) 用作铃蟾肽受体亚型-3调节剂的取代的二氮杂磺酰胺类化合物
CN105814064A (zh) 作为胆固醇酯转运蛋白的抑制剂的稠合双环异噁唑啉类
CN104334193A (zh) 生长激素释放肽受体反向激动剂或拮抗剂用于治疗睡眠障碍的用途
MXPA06002029A (es) N-aril-2-cianooxazolidinonas y sus derivados.
JP6327515B2 (ja) ナルコレプシーまたは摂食障害の治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1202459

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150204

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1202459

Country of ref document: HK